Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Niki BioSolutions's FCF Margin % or its related term are showing as below:
During the past 9 years, the highest FCF Margin % of Niki BioSolutions was -959.14%. The lowest was -4203.66%. And the median was -1778.70%.
NIKI's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.28 * Ranked among companies with meaningful FCF Margin % only.
Niki BioSolutions FCF Margin % Related Terms
Niki BioSolutions FCF Margin % Historical Data
* Premium members only.
The historical data trend for Niki BioSolutions's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Niki BioSolutions's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niki BioSolutions FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niki BioSolutions's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Niki BioSolutions's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niki BioSolutions (NIKI) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Niki BioSolutions and its competitors. According to the industry distribution chart, Niki BioSolutions ranks #999999 out of 950 companies in the Biotechnology industry.
Is Niki BioSolutions' FCF Margin % too high?
Niki BioSolutions' current FCF Margin % is 0.00%. Based on the distribution chart, Niki BioSolutions ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Niki BioSolutions has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Niki BioSolutions' FCF Margin % compare to LABT and NCNA?
According to the Biotechnology industry distribution chart, Niki BioSolutions ranks #999999 out of 950 companies for FCF Margin %. This places Niki BioSolutions in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Niki BioSolutions and its competitors. Niki BioSolutions's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niki BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Niki BioSolutions (NIKI) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.69, compared to a current price of $9.54 — trading 18.4% below its estimated fair value. The current FCF Margin % is 0.00%. Niki BioSolutions' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Niki BioSolutions (NIKI), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niki BioSolutions (NIKI) Overvalued in 2026?
Based on GuruFocus' analysis, Niki BioSolutions stock appears to be undervalued.
The current stock price of $9.54 is trading 18.4% below its estimated GF Value™ of $11.69.
GuruFocus considers Niki BioSolutions to be Modestly Undervalued.
Key valuation signals for NIKI:
FCF Margin %: 0.00%
GF Value™: $11.69 vs. price of $9.54 (18.4% below fair value)
No single metric tells the full story. See the NIKI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
56GF Score
Get the complete analysis for NIKI
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NIKI has been successfully added to your 
